https://scholars.lib.ntu.edu.tw/handle/123456789/590435
Title: | Comparison of the 2017 Taiwan lipid guidelines and the Western lipid guidelines for high risk patients | Authors: | Li Y.-H. Yeh H.-I. JIANN-SHING JENG Charng M.-J. |
Keywords: | Dyslipidemia; Guideline; Statin; Taiwan | Issue Date: | 2018 | Journal Volume: | 81 | Journal Issue: | 10 | Start page/Pages: | 853-859 | Source: | Journal of the Chinese Medical Association | Abstract: | Dyslipidemia is a major contributor in initiation, development and progression of atherosclerotic cardiovascular disease (ASCVD). Most lipid guidelines are from Europe and America and centered on the reduction of atherogenic lipids levels through lifestyle intervention and pharmacotherapy. Recently, the 2017 Taiwan lipid guidelines for high risk patients was published to facilitate the control of dyslipidemia in patients that are highly susceptible to ASCVD, including patients with preexisting ASCVD, diabetes, chronic kidney disease and familial hypercholesterolemia. Most recommendations outlined in the 2017 Taiwan lipid guidelines for high risk patients are in concordance with those of Western guidelines. However, based on evidence from the studies originating from Asia and local expert opinions, there are some recommendations different from the other guidelines. The purpose of the current review is to compare the similarities and differences between the perspectives of the 2017 Taiwan lipid guidelines for high risk patients and other Western guidelines in individuals at high risk of ASCVD. The definitions of high risk groups and treatment goals defined to achieve ASCVD risk reduction are specifically compared. ? 2018 |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85049337985&doi=10.1016%2fj.jcma.2018.05.003&partnerID=40&md5=8aa78e3d1dc5538463eb6244b9cd7864 https://scholars.lib.ntu.edu.tw/handle/123456789/590435 |
ISSN: | 17264901 | DOI: | 10.1016/j.jcma.2018.05.003 | SDG/Keyword: | ezetimibe; ezetimibe plus simvastatin; high density lipoprotein cholesterol; hydroxymethylglutaryl coenzyme A reductase inhibitor; hypocholesterolemic agent; lipid; low density lipoprotein cholesterol; proprotein convertase 9; serine proteinase inhibitor; simvastatin; triacylglycerol; lipid; acute coronary syndrome; brain hemorrhage; brain ischemia; cardiovascular risk; cerebrovascular accident; chronic kidney failure; comparative study; coronary artery atherosclerosis; diabetes mellitus; diabetic patient; disease severity; dyslipidemia; familial hypercholesterolemia; high risk patient; human; lifestyle modification; peripheral occlusive artery disease; practice guideline; Review; risk assessment; risk reduction; secondary prevention; Taiwan; western medicine; atherosclerosis; blood; cardiovascular disease; dyslipidemia; practice guideline; Taiwan; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus; Dyslipidemias; Humans; Hyperlipoproteinemia Type II; Lipids; Practice Guidelines as Topic; Renal Insufficiency, Chronic; Taiwan |
Appears in Collections: | 醫學院附設醫院 (臺大醫院) |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.